Last reviewed · How we verify
NCT04959019: EMemRE
Exercise for Memory Rehabilitation in Epilepsy
NA trial testing Supervised combined endurance and resistance training (CERT) in Epilepsy, Generalized in 71 participants. Completed in 18 February 2026.
18 February 2026
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 71 |
| Start date | 21 July 2021 |
| Primary completion | 18 February 2026 |
| Estimated completion | 18 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Supervised combined endurance and resistance training (CERT)
- Delayed supervised combined endurance and resistance training (CERT)
Conditions studied
- Epilepsy, Generalized — all drugs for Epilepsy, Generalized →
- Memory Impairment — all drugs for Memory Impairment →
Sponsor
University of Alabama at Birmingham
Who can join
Adults 18 to 65, any sex, with Epilepsy, Generalized or Memory Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine how effective a 6-week exercise program is for improving memory compared to a no-intervention control group, investigate the brain changes that may be responsible for memory improvements, and determine if the memory benefits and brain changes are retained 6 weeks after completing the exercise intervention in people with Idiopathic generalized epilepsy (IGE).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Do people with epilepsy want to participate in an exercise intervention randomized controlled trial? - Results of a brief survey and its preliminary application.
Mitchell BS, Puzzo C, Morgan CJ, Szaflarski JP, et al · · 2023 · cited 2× · PMID 38025406 · DOI 10.1016/j.ebr.2023.100632 -
Cerebral blood flow increases in idiopathic generalized epilepsy and its relationship with mood dysfunction.
Lien Y, Sharma AA, Willoughby WR, Moyana A, et al · · 2025 · cited 1× · PMID 40296378 · DOI 10.1002/epi4.70049
Verify or expand the search:
- PubMed search for NCT04959019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy, Generalized
Currently open trials in the same condition.
- NCT06769659 — A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Abse · Phase 2 · recruiting
- NCT06399952 — Baker Gordon Syndrome Natural History Study · recruiting
- NCT06579573 — ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. · Phase 3 · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04959019 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04959019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing